SGO Annual Meeting | Conference

Maintenance Niraparib Extends PFS Without Symptoms, Toxicities in Recurrent Ovarian Cancer

March 17th 2019

Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.

Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer

March 28th 2018

First-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.

Similar Efficacy Across PARP Inhibitors in Ovarian Cancer, But Safety Analysis Favors Olaparib

March 28th 2018

Currently approved PARP inhibitors have demonstrated similar efficacy in the setting of maintenance therapy for patients with ovarian cancer but differ with respect to the type and frequency of grade 3/4 adverse events, results of a network meta-analysis suggested.

Olaparib/Durvalumab Combo Active in Relapsed Ovarian Cancer

March 27th 2018

Combination therapy with the PARP inhibitor olaparib and the PD-L1 inhibitor durvalumab induced objective responses in more than 70% of patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.

Dr. Slomovitz Discusses a Study of Everolimus/Letrozole or Hormonal Therapy in Endometrial Cancer

March 27th 2018

Brian M. Slomovitz, MD, gynecologic oncologist, Sylvester Comprehensive Cancer Center, University of Miami, discusses GOG 3007, a randomized phase II study of everolimus (Afinitor) and letrozole or hormonal therapy (medroxyprogesterone acetate/tamoxifen) in women with advanced, persistent or recurrent endometrial carcinoma during the 2018 Society of Gynecologic Oncology Annual Meeting.

Dr. Mark Discusses an Ultra-Restrictive Opioid Prescription Protocol in Postoperative Patients

March 27th 2018

Jaron Mark, MD, gynecologic oncology fellow, Roswell Park Comprehensive Cancer Center, discusses the implementation of an ultra-restrictive opioid prescription protocol (UROPP) in patients undergoing major gynecologic surgery, which radically decreased dispensed opioids without reducing pain control, during the 2018 Society of Gynecologic Oncology Annual Meeting.

Pembrolizumab Plus Niraparib Shows Promise in Ovarian Cancer

March 27th 2018

Patients with platinum-resistant/refractory ovarian cancer had durable responses with the combination of the PARP inhibitor niraparib (Zejula) and pembrolizumab (Keytruda).

Pembrolizumab Plus Mirvetuximab Soravtansine Active in Ovarian Cancer

March 27th 2018

Almost half of patients with platinum-resistant ovarian cancer had objective responses to combination therapy with pembrolizumab plus the antifolate antibody-drug conjugate mirvetuximab soravtansine.

Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

March 26th 2018

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Trastuzumab Active in Uterine Serous Carcinoma

March 26th 2018

Patients with HER2-positive uterine serous carcinoma had a greater than 50% improvement in progression-free survival when treated with trastuzumab and chemotherapy versus chemotherapy alone, a small randomized trial showed.

Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer

March 26th 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

ASCO and ESMO Value Frameworks May Be Beneficial in Determining Best Maintenance Therapies for Ovarian Cancer

March 26th 2018

To access the value of the maintenance therapies and biomarkers to direct treatment for patients with platinum-sensitive recurrent ovarian cancer, investigators used ASCO’s Net Health Benefit and ESMO’s Magnitude of Clinical Benefit Scale.

Dr. Mirza Discusses Niraparib Dose Modifications for Patients With Low Body Weight

March 26th 2018

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.

Low Body Weight, Platelet Counts Predict Niraparib Dose Reductions for Ovarian Cancer

March 25th 2018

Baseline body weight and platelet counts were early predictors for future AE-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Protocol Effects Big Drop in Opioid Use After Gynecologic Surgery

March 25th 2018

Implementation of an "ultra-restrictive" opioid prescription protocol for gynecologic surgery led to an 89% reduction in the number of opioid tablets dispensed at discharge and a high rate of patient satisfaction.

Dr. Monk on Choosing Between PARP Inhibitors in Ovarian Cancer

March 25th 2018

Bradley J. Monk, MD, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses how to decide which PARP inhibitor to use when treating a patient with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Checkpoint Inhibitors Induce Higher Rate of Adverse Events in Recurrent Ovarian Cancer

March 25th 2018

The use of immune checkpoint inhibitors in women with recurrent ovarian cancer has a clinical benefit but a higher rate of adverse events than previously reported in other tumor types.

Immunotherapy AXAL Tops Survival Mark in Cervical Cancer

March 16th 2017

An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.

Maintenance Chemotherapy Yields No OS Benefit in Ovarian Cancer

March 15th 2017

Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.

Maintenance Olaparib Shows Impressive PFS Benefit for BRCA+ Ovarian Cancer

March 15th 2017

Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.